Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Avigan

Showing results (91-100 of 114) with videos related to

Pageof 12
Sort By:
Blood|January 28, 2017
MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemiaAthalia Rachel Pyzer, Dina Stroopinsky, Hasan Rajabi, et al.
Bone Marrow Transplantation|October 17, 2019
A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiationZachariah DeFilipp, Shuli Li, David Avigan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 7, 2012
Phase II trial of parathyroid hormone after double umbilical cord blood transplantationKaren Ballen, Adam M Mendizabal, Corey Cutler, et al.
Cell Research|April 27, 2019
Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapyVera Mugoni, Riccardo Panella, Giulia Cheloni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2013
Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patientsJacalyn Rosenblatt, Irit Avivi, Baldev Vasir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyAlexander M Lesokhin, Stephen M Ansell, Philippe Armand, et al.
Blood Advances|November 22, 2021
GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trialVincent T Ho, Haesook T Kim, Jennifer Brock, et al.
Cytotherapy|December 13, 2016
Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipientsSarah Nikiforow, Shuli Li, Karen Snow, et al.
Blood|June 2, 2020
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantationMatthew S Davids, Haesook T Kim, Caitlin Costello, et al.
Science Translational Medicine|December 8, 2021
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistenceAfroditi Katsarou, Maria Sjöstrand, Jyoti Naik, et al.
Pageof 12

Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
Blood|January 28, 2017
MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemiaAthalia Rachel Pyzer, Dina Stroopinsky, Hasan Rajabi, et al.
Bone Marrow Transplantation|October 17, 2019
A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiationZachariah DeFilipp, Shuli Li, David Avigan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 7, 2012
Phase II trial of parathyroid hormone after double umbilical cord blood transplantationKaren Ballen, Adam M Mendizabal, Corey Cutler, et al.
Cell Research|April 27, 2019
Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapyVera Mugoni, Riccardo Panella, Giulia Cheloni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2013
Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patientsJacalyn Rosenblatt, Irit Avivi, Baldev Vasir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyAlexander M Lesokhin, Stephen M Ansell, Philippe Armand, et al.
Blood Advances|November 22, 2021
GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trialVincent T Ho, Haesook T Kim, Jennifer Brock, et al.
Cytotherapy|December 13, 2016
Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipientsSarah Nikiforow, Shuli Li, Karen Snow, et al.
Blood|June 2, 2020
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantationMatthew S Davids, Haesook T Kim, Caitlin Costello, et al.
Science Translational Medicine|December 8, 2021
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistenceAfroditi Katsarou, Maria Sjöstrand, Jyoti Naik, et al.
Pageof 12